You are in: eMedicine Specialties > Emergency Medicine > INFECTIOUS DISEASES Tick-Borne Diseases, Q FeverArticle Last Updated: Oct 16, 2006AUTHOR AND EDITOR INFORMATIONAuthor: Jonathan A Edlow, MD, Associate Professor of Medicine, Department of Emergency Medicine, Harvard Medical School; Associate Chief, Department of Emergency Medicine, Beth Israel Deaconess Medical Center Jonathan A Edlow is a member of the following medical societies: American College of Emergency Physicians Editors: Dan Danzl, MD, Chair, Department of Emergency Medicine, Professor, University of Louisville Hospital; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Jon Mark Hirshon, MD, MPH, Associate Professor, Department of Emergency Medicine, University of Maryland School of Medicine; John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center; Charles V Pollack, Jr, MD, MA, FACEP, Professor, Department of Emergency Medicine, University of Pennsylvania College of Medicine; Chairman, Department of Emergency Medicine, Pennsylvania Hospital Author and Editor Disclosure Synonyms and related keywords: Q fever, tick-borne disease, Coxiella burnetii, C burnetii, fever, vector-borne disease, tick bite, acute Q fever, chronic Q fever, febrile illness INTRODUCTIONBackgroundFirst described in 1935 by Derrick, Q fever is an acute infectious disease. Derrick investigated a cluster of febrile illnesses of unknown etiology in Australian abattoir workers and subsequently named the malady Q (for query) fever. Most commonly spread by means of inhalation or ingestion, Q fever can also be tick-borne. Q fever usually presents as an undifferentiated febrile illness with predominant respiratory or hepatic manifestations. PathophysiologyThe causative organism is Coxiella burnetii. Classically grouped with the rickettsial organisms, C burnetii differs from the other organisms in that group; in fact, its genetic makeup is more closely related to Legionella species than to the other Rickettsia species. C burnetii is a small gram-negative organism that lives inside acidic lysosomes, a point that has therapeutic implications. The organism exists in 2 forms, phase I and phase II, which are analogous to the lipopolysaccharide rough and smooth phase of Enterobacteriaceae organisms. The phase I form is isolated from animals and is the infectious form. The organism is remarkably resistant to environmental extremes. A spore form also exists. The reservoir in nature includes mammals, birds, and ticks; the last is an important vector in infecting mammals. A strong association between the disease and exposure to farm animals exists. Furthermore, because the organism is reactivated in pregnant animals, a strong association between the disease and contact with parturient animals (especially cows, sheep, goats, dogs, cats, rabbits) also exists. Aerosol from newborn animals and their placentas can spread Q fever. Other modes of transmission include aerosol from contaminated wool, hides, and dust; ingestion of raw milk or goat cheese; blood transfusions; and tick bites. Even wind patterns may make a difference by spreading aerosolized organisms downwind. Outbreaks of Q fever have occurred in an industrial setting from straw board that had been drilled open during part of the construction process. Recent studies in patients with chronic Q fever in which polymerase chain reaction (PCR) was used to detect C burnetii DNA revealed evidence that the organism persists in human liver, blood monocytes, and most commonly, bone marrow. FrequencyUnited StatesQ fever is present throughout the United States. The precise incidence is unknown. Although the actual frequency is likely low, the Centers for Disease Control and Prevention still regularly report cases that occur in the United States. InternationalQ fever exists worldwide. A seroprevalence study of blood donors in Marseille, France, showed that 4% of donors had antibodies to C burnetii. Similar studies in other European countries have shown figures of 5-30%, with lower figures seen in urban areas and higher figures in rural zones. Mortality/Morbidity
AgePatients of all ages can contract Q fever. The incidence, as determined by the age at which seroconversion of blood donors occurs, can be deceptive because children, elderly persons, and sick persons do not donate blood. CLINICALHistoryQ fever can manifest various signs; no one classic presentation exists. The major clue is the epidemiologic circumstance, exposure to parturient mammals or their newborn, and tick bites. The most common presentation of Q fever may vary with geography. For example, in the Basque region of northern Spain, pneumonia is a common finding, whereas in southern Spain, hepatitis predominates. Finding with acute and chronic Q fever may include the following:
PhysicalPhysical findings vary with the presenting clinical syndrome. No pathognomonic findings exist.
CausesThe cause of Q fever is infection with the bacteria C burnetii. In this age of concern for terrorism with biological agents, Q fever is on the list of possible agents. It is highly infectious and spread by aerosol. Although the mortality rate is low, it could provoke considerable disability and disorganization. Initial diagnosis might be delayed by the fact that it is so uncommon in most locations. DIFFERENTIALSHepatitis Legionnaires Disease Myocarditis Pericarditis and Cardiac Tamponade Pneumonia, Bacterial Pneumonia, Viral Tick-Borne Diseases, Ehrlichiosis Tick-Borne Diseases, Introduction Tick-Borne Diseases, Relapsing Fever Tick-Borne Diseases, Rocky Mountain Spotted Fever Tick-Borne Diseases, Tularemia
|
| Drug Name | Doxycycline (Bio-Tab, Doryx, Vibramycin) |
|---|---|
| Description | DOC for Q fever. Interferes with bacterial cell wall synthesis during active multiplication, causing cell wall death and resultant bactericidal activity against susceptible bacteria. |
| Adult Dose | Acute infection: 200 mg PO/IV immediately and 100 mg hs, followed by 100 mg bid for 3 d Alternatives: 300 mg PO/IV immediately then 300 mg in 1 h, or 100 mg PO/IV bid for 7 d |
| Pediatric Dose | <8 years: Not recommended >8 years: 2-5 mg/kg/d PO/IV qd or divided bid; not to exceed 200 mg/d |
| Contraindications | Documented hypersensitivity; severe hepatic dysfunction |
| Interactions | Bioavailability decreases with antacids containing aluminum, calcium, magnesium, iron, or bismuth subsalicylate; tetracyclines can increase hypoprothrombinemic effects of anticoagulants; tetracyclines can decrease effects of oral contraceptives, causing breakthrough bleeding and increased risk of pregnancy |
| Pregnancy | D - Unsafe in pregnancy |
| Precautions | Photosensitivity (with prolonged exposure to sunlight or tanning equipment); reduce dose in renal impairment; consider determining drug serum levels in prolonged therapy; tetracycline use during tooth development (last one half of pregnancy through age 8 y) can permanently discolor of teeth; Fanconilike syndrome may occur with outdated tetracyclines |
| Drug Name | Tetracycline (Sumycin) |
|---|---|
| Description | Treats susceptible bacterial infections of both gram-positive and gram-negative organisms, as well as infections caused by Mycoplasma, Chlamydia, and Rickettsia organisms. Inhibits bacterial protein synthesis by binding with 30S and possibly 50S ribosomal subunits of susceptible bacteria. |
| Adult Dose | 250-500 mg PO q6h Mild-to-moderate infections: 500 mg PO bid or 250 mg PO qid for 7-14 d Severe infections: 500 mg PO qid for 7-14 d |
| Pediatric Dose | <8 years: Not recommended >8 years: 10-20 mg/lb/d (25-50 mg/kg) PO divided qid |
| Contraindications | Documented hypersensitivity; severe hepatic dysfunction |
| Interactions | Bioavailability decreases with antacids containing aluminum, calcium, magnesium, iron, or bismuth subsalicylate; can decrease effects of oral contraceptives, causing breakthrough bleeding and increased risk of pregnancy; tetracyclines can increase hypoprothrombinemic effects of anticoagulants |
| Pregnancy | D - Unsafe in pregnancy |
| Precautions | Photosensitivity (with prolonged exposure to sunlight or tanning equipment); reduce dose in renal impairment; consider determining drug serum levels in prolonged therapy; tetracycline use during tooth development (last one half of pregnancy through age 8 y) can permanently discolor teeth; Fanconilike syndrome may occur with outdated tetracyclines |
| Drug Name | Chloramphenicol (Chloromycetin) |
|---|---|
| Description | Used in patients who do not tolerate tetracycline. |
| Adult Dose | 50-100 mg/kg/d PO/IV divided q6h for 10 d; not to exceed 4 g/d |
| Pediatric Dose | 50-75 mg/kg/d PO/IV divided q6h |
| Contraindications | Documented hypersensitivity |
| Interactions | Concurrently with barbiturates, chloramphenicol serum levels may decrease while barbiturate levels may increase, causing toxicity; manifestations of hypoglycemia may occur with sulfonylureas; rifampin may reduce serum levels, presumably because of hepatic enzyme induction; may increase effects of anticoagulants; may increase serum hydantoin levels, possibly resulting in toxicity; levels may be increased or decreased |
| Pregnancy | D - Unsafe in pregnancy |
| Precautions | Use only for indicated infections or as prophylaxis for bacterial infections; serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia, granulocytopenia) can occur; perform baseline and periodic blood studies approximately every 2 d during therapy; discontinue with reticulocytopenia, leukopenia, thrombocytopenia, anemia, or findings attributable to chloramphenicol; adjust dose in liver or kidney dysfunction; caution in pregnancy at term or during labor because of potential toxic effects on fetus (gray syndrome) |
| Drug Name | Sulfamethoxazole and trimethoprim (Bactrim, Bactrim DS, Septra, Septra DS) |
|---|---|
| Description | Inhibits bacterial growth by inhibiting synthesis of dihydrofolic acid. This would be a drug to use in pregnant women after consultation with the patient's obstetrician and an infectious disease specialist. |
| Adult Dose | 320 mg TMP/1600 mg SMZ PO q12h |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; megaloblastic anemia due to folate deficiency |
| Interactions | May increase PT when used with warfarin (perform coagulation tests and adjust dose accordingly); coadministration with dapsone may increase blood levels of both drugs; coadministration of diuretics increases incidence of thrombocytopenia purpura in elderly persons; phenytoin levels may increase with coadministration; may potentiate effects of methotrexate in bone marrow depression; hypoglycemic response to sulfonylureas may increase with coadministration; may increase levels of zidovudine |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Do not use during last trimester of pregnancy because of potential toxicity to newborn (eg, jaundice, hemolytic anemia, kernicterus) Dosage adjustments (adult adjustments) CrCl (mL/min) 80-50: Recommended IV dose q18h CrCl 50-10: Recommended IV dose q24h CrCl <10: Not recommended HD: 4-5 mg/kg after HD During peritoneal dialysis: 0.16-0.8 g q48h Discontinue at first appearance of skin rash or sign of adverse reaction; obtain CBCs frequently; discontinue therapy if significant hematologic changes occur; goiter, diuresis, and hypoglycemia may occur with sulfonamides; prolonged IV infusions or high doses may cause bone marrow depression (if signs occur, give 5-15 mg/d leucovorin); caution in folate deficiency (eg, chronic alcoholics, elderly persons, those receiving anticonvulsant therapy, or those with malabsorption syndrome); hemolysis may occur in G-6-PD deficient individuals; AIDS patients may not tolerate or respond to TMP-SMZ; caution in renal or hepatic impairment (perform urinalyses and renal function tests during therapy); give fluids to prevent crystalluria and stone formation |
Treatment of Q fever is symptomatic and supportive. Bed rest and mild analgesic-antipyretic therapy often are helpful in relieving the lethargy, malaise, and fever associated with the disease.
| Drug Name | Aspirin (Bayer Aspirin, Bufferin, Anacin, Ascriptin) |
|---|---|
| Description | Enhances dissipation of heat by vasodilating peripheral vessels, causing a decrease in body temperature. Also acts on hypothalamus heat-regulating center to reduce fever. |
| Adult Dose | 325-650 mg PO q4-6h; not to exceed 4 g/d |
| Pediatric Dose | 10-15 mg/kg/dose PO q4-6h; not to exceed 60-80 mg/kg/d |
| Contraindications | Documented hypersensitivity; liver damage; hypoprothrombinemia; vitamin K deficiency; bleeding disorders; asthma; children ( <16 y) with flu (association with Reye syndrome) |
| Interactions | Effects may decrease with antacids and urinary alkalinizers; corticosteroids decrease salicylate serum levels; additive hypoprothrombinemic effects and increased bleeding time may occur with coadministration of anticoagulants; may antagonize uricosuric effects of probenecid and increase toxicity of phenytoin and valproic acid; doses > 2 g/d may potentiate glucose-lowering effect of sulfonylurea drugs |
| Pregnancy | D - Unsafe in pregnancy |
| Precautions | May cause transient decrease in renal function and aggravate chronic kidney disease; avoid in severe anemia, history of blood coagulation defects, or anticoagulant therapy |
| Drug Name | Ibuprofen (Motrin, Nuprin, Advil, Ibuprin) |
|---|---|
| Description | One of the few NSAIDs indicated for reduction of fever. |
| Adult Dose | 200-400 mg PO q4-6h while symptoms persist; not to exceed 3.2 g/d |
| Pediatric Dose | <6 months: Not established 6 months to 12 years: 30-70 mg/kg/d PO divided tid/qid; start with lower dose and titrate to maximum of 2.4 g/d >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency; high risk of bleeding |
| Interactions | Coadministration with aspirin increases risk of serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; monitor PT closely (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Category D in third trimester of pregnancy; caution in congestive heart failure, hypertension, decreased renal and hepatic function; caution in anticoagulation abnormalities or during anticoagulant therapy |
| Drug Name | Acetaminophen (Aspirin Free Anacin, Tylenol, Feverall) |
|---|---|
| Description | DOC for treatment of pain in patients with documented hypersensitivity to aspirin, NSAIDs, or upper GI disease and in those taking oral anticoagulants. Inhibits action of endogenous pyrogens on heat-regulating centers. |
| Adult Dose | 325-650 mg PO q4-6h or 1000 mg PO tid/qid; not to exceed 4 g/d Alternative: 1000 mg PO tid/qid; not to exceed 4 g/d |
| Pediatric Dose | <12 years: 10-15 mg/kg/dose PO q4-6h prn; not to exceed 2.6 g/d >12 years: 325-650 mg PO q4h; not to exceed 5 doses in 24 h |
| Contraindications | Documented hypersensitivity; known G-6-P deficiency |
| Interactions | Rifampin can reduce analgesic effects; coadministration with barbiturates, carbamazepine, hydantoins, and isoniazid may increase hepatotoxicity |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Hepatotoxicity possible in chronic alcoholism with various doses; severe or recurrent pain or high or continued fever may indicate serious illness; may contain acetaminophen, and combined use may cause cumulative acetaminophen doses to exceed recommended maximum doses |
Tick-Borne Diseases, Q Fever excerpt
Article Last Updated: Oct 16, 2006